Comprehensive Genomic Landscape Across Histopathological Stages of Lung Adenocarcinoma: A Retrospective Cross‐Sectional Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: The genomic features associated with the histopathological spectrum from precursor glandular lesions to invasive lung adenocarcinoma remain incompletely characterized. In this retrospective cross-sectional study, we performed targeted sequencing of 823 resected lesions from 823 patients, including 149 precursor glandular lesions (11 atypical adenomatous hyperplasia [AAH] and 138 adenocarcinoma in situ [AIS]), 252 minimally invasive adenocarcinoma (MIA), and 422 invasive adenocarcinoma (IAC). EGFR mutation frequency increased across precursor lesions, MIA, and IAC (44%, 57%, and 65%), whereas ERBB2 decreased (20%, 13%, and 6%); TP53 was markedly enriched in IAC (3%, 6%, and 35%). Cell-cycle and homologous recombination repair (HRR) pathway alterations were likewise more frequent in IAC and in Grade 3 tumors. Solid nodules showed higher TP53, cell-cycle, and HRR alteration frequencies than ground-glass-predominant lesions. IAC displayed prominent tobacco-associated single-base substitutions 4 (SBS4) and APOBEC-associated SBS2 signatures, whereas MIA signatures showed lower similarity to canonical COSMIC signatures. Smoking was associated with a distinct genomic profile and higher tumor mutational burden (TMB). TMB and PD-L1 tumor proportion score varied according to gene mutation status. High TMB and KRAS/STK11/KEAP1-related mutation groups were associated with poorer survival. These findings delineate histology-associated genomic patterns across the lung adenocarcinoma spectrum without implying direct temporal evolution.
Source: MedComm
DOI: 10.1002/mco2.71150
Institutions: Sun Yat-sen University, Sun Yat-sen Memorial Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: lung adenocarcinoma, histopathological spectrum, atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, EGFR mutation, ERBB2, TP53, cell cycle pathway, homologous recombination repair, mutational signatures, APOBEC signature, smoking, tumor mutational burden, PD-L1 tumor proportion score, KRAS, STK11, Keap1, survival
Open Access status: gold
Estimated APC paid: $3,500
Award: G1422151897
OpenAlex ID: W7235696654
